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Abstract Mutations in the two breast cancer suscepti-
bility genes BRCA1 and BRCA2 are associated with
increased risk of breast and ovarian cancer. Patients with
mutations in both genes are rarely reported and often
involve Ashkenazi founder mutations. Here we report the
ﬁrst identiﬁcation of a Danish breast and ovarian cancer
family heterozygote for mutations in the BRCA1 and
BRCA2 genes. The BRCA1 nucleotide 5215G[
A/c.5096G[A mutation results in the missense mutation
Arg1699Gln, while the BRCA2 nucleotide 859 ? 4A[
G/c.631 ? 4A[G is novel. Exon trapping experiments
and reverse transcriptase (RT)–PCR analysis revealed that
the BRCA2 mutation results in skipping of exon 7, thereby
introducing a frameshift and a premature stop codon. We
therefore classify the mutation as disease causing. Since the
BRCA1 Arg1699Gln mutation is also suggested to be dis-
ease-causing, we consider this family double heterozygote
for BRCA1 and BRCA2 mutations.
Keywords BRCA1   BRCA2   Breast cancer  
Double heterozygote   Ovarian cancer   Mutation
Abbreviations
BIC Breast cancer information core
DBCG Danish breast cancer cooperative group
RT–PCR Reverse transcriptase–PCR
Introduction
Germ-line mutations in BRCA1 (MIM# 113705) and
BRCA2 (MIM# 600185) confer a high risk of breast and
ovarian cancer. A disease causing mutation will result in
60–80% risk of developing breast cancer for a female
carrier, while the risk of getting ovarian cancer is 20–40%
or 10–20% with a BRCA1 or BRCA2 mutation, respectively
[reviewed in [1]]. Most mutations in BRCA1 and BRCA2
have been listed in Breast Cancer Information Core (BIC)
[2], and includes pathogenic mutations such as frameshift,
nonsense, and splicing mutations, of which several have
been identiﬁed in Danish breast and/or ovarian cancer
patients [3–6]. Moreover, several founder mutations have
been identiﬁed in a variety of different populations,
including Ashkenazi Jews, Icelanders and Greenlandic
Inuits [7–9]. A large number of BRCA1/BRCA2 missense,
silent and intron mutations are of unknown signiﬁcance. To
enable the clinicians to give the affected patients satisfac-
tory advice about preventive care, assessment of these
mutations of unknown signiﬁcance by functional studies
are advised. Intron variants can be analysed by RT–PCR or
by examining the splicing pattern in vitro using a mini gene
system (reviewed in [10]). Here we report the ﬁrst identi-
ﬁcation of a Danish family with germ-line mutations in
both the BRCA1 and BRCA2 genes. The BRCA1 nucleotide
5215G[A/c.5096G[A mutation results in the mis-
sense mutation Arg1699Gln, while the BRCA2 nucleotide
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DOI 10.1007/s10689-010-9345-6859 ? 4A[G/c.631 ? 4A[G mutation is novel. Func-
tional characterization of the BRCA2 nucleotide
859 ? 4A[G/c.631 ? 4A[G mutation by exon trap-
ping experiments and RT–PCR analysis, revealed that the
mutation results in skipping of exon 7 and leads to incor-
poration of 18 out of frame amino acids followed by a stop
codon. We therefore classify the mutation as disease
causing. Since the BRCA1 Arg1699Gln mutation is also
suggested to be disease-causing, we consider this family
double heterozygote for BRCA1 and BRCA2 mutations.
Materials and methods
Patients
A 59 year-old woman with breast cancer (53) and ovarian
cancer (59) was referred to genetic counselling. The family
had two other cases of breast cancer (Fig. 1). Following
verbal and written consent, blood samples were collected
from the proband for mutation screening and after renewed
consent a third blood sample was collected for RNA
analysis. The family history was veriﬁed using the registry
of the DBCG (Danish Breast Cancer Cooperative Group),
hospital medical records and pathology reports, and genetic
counselling was provided for family members.
BRCA1 and BRCA2 screening
Genomic DNA was puriﬁed from whole blood using the
QIAamp DNA mini kit (Qiagen), and from parafﬁn-
embedded tissue using the Chemagic DNA tissue kit
(Chemagen) according to the manufacturer’s instructions.
BRCA1 and BRCA2 screening was performed as recently
described [4]. Sequence variations were veriﬁed in a new
blood sample. The BRCA1 mutation is numbered according
to GenBank accession number U14680, in which A in the
AUG start codon has number 120, while the BRCA2
mutation is numbered according to GenBank accession
number NM_000059, in which A in the AUG start codon
has number 229. Moreover, the BRCA1 and BRCA2
mutations are numbered according to GenBank accession
number NC_00017.10 and NC_000013.9 using the guide-
lines from the Human Genetic Variation Society.
In silico analyse
In silico prediction of the functional consequence of the
missense variants was performed using SIFT (Sorting
Intolerant From Tolerant): http://blocks.fhcrc.org/sift/SIFT.
html [11] Polyphen: http://coot.embl.de/PolyPhen/ [12] and
PMut: http://mmb2.pcb.ub.es:8080/PMut/ [13]. The fol-
lowing three splice site prediction programmes were used to
predict the effect of the BRCA2 IVS7 ? 4A[G mutation
on the efﬁciency of splicing: www.fruitﬂy.org/seq_tools/
splice.html [14], www.cbs.dtu.dk/services/NetGene2 [15]
and www.umd.be/SSF [16]. The genomic sequence span-
ning the BRCA2 nucleotide 859 ? 4A [G/c.631 ? 4
A[G mutation was submitted according to the guidelines
of each programme and default settings were used in all
predictions.
Exon trapping analysis
pSPL3-BRCA2-wild type plasmid and pSPL3-BRCA2-
mutant plasmid, containing BRCA2 exon 7 and ﬂanking
intron sequences, was constructed by cloning genomic
DNA from the proband using the following primers
BRCA2-F, 50-GATCACCTCGAGCGTTATACCTTTGCC
CTGAGATTTA -30 and BRCA2-R 50-GATCACCTG-
CAGTTTAATGCCCCAATTACCAC -30 into the pSPL3
splicing vector as recently described [5]. All constructs
were veriﬁed by sequencing. COS7 cells were transfected
using Fugene 6 (Roche) with either pSPL3-BRCA2-wild-
type or pSPL3-BRCA2-mutant plasmids, RNA was puri-
ﬁed and RT–PCR was performed as recently described [5].
RNA analysis
A fresh blood sample was obtained from the patient. Total
cellular RNA was isolated with Trizol (Invitrogen) accord-
ing to the manufacturer’s instructions. For reverse tran-
scription–PCR (RT–PCR), cDNA was synthesized using
randomhexamerprimersandM-MuLVreversetranscriptase
(New England Biolabs) as described by the supplier. The
cDNA was ampliﬁed with the BRCA2 speciﬁc prim-
ers 50-CAAATTAGACTTAGGAAGGAATGTTCC-30 and
50-CATGAGGAAATACAGTTTCAGATGC-30. The sam-
ples were separated by agarose gel electrophoresis and
Fig. 1 Family pedigree. Breast and ovarian cancer are indicated as
well as the age at diagnosis. Diagonal slash indicates deceased, while
the proband is indicated with an arrow. Mutation positive individuals
are indicated with ?. ?/? indicates individuals with both mutations
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123visualized by ethidium bromide staining. Finally, the bands
were puriﬁed, cloned into pCR-Blunt II-TOPO (Invitrogen)
and sequenced using an ABI3730 DNA analyzer (Applied
Biosystems).
Results
The proband was referred to genetic counselling, since she
was diagnosed with breast cancer at the age of 53 and
ovarian cancer at the age of 59. Her deceased father and
deceased sister were diagnosed with breast cancer at the
age of 76 and 43, respectively (Fig. 1). Blood samples were
collected, genomic DNA was puriﬁed and the entire coding
region and the exon–intron boundaries of BRCA1 and
BRCA2 were screened by dHPLC and sequencing. More-
over, the DNA was examined for large genomic rear-
rangements by MLPA analysis. The analysis identiﬁed a
BRCA1 nucleotide 5215G[A/c.5096G[A mutation
(Fig. 2a), which introduces a missense mutation chang-
ing amino acid 1699 from an arginine to a glutamine.
Moreover, a novel BRCA2 nucleotide 859 ? 4A[
G/c.631 ? 4A[G mutation of unknown signiﬁcance
were identiﬁed (Fig. 2b). Both mutations were also iden-
tiﬁed in the proband’s two children. Moreover, analysis of
genomic DNA from parafﬁn-embedded cancer tissue from
the probands deceased father revealed that both mutations
were inherited from him (Fig. 1). To indicate whether the
mutations could be disease-causing, three different protein
prediction programmes were used to predict the functional
consequence of the BRCA1 Arg1699Gln mutation [11–13],
while three different splice site prediction programmes
were used to predict the effect of the BRCA2 nucleotide
859 ? 4A[G/c.631 ? 4A[G mutation on splicing of
exon 7 [14–16]. All three protein prediction programmes
estimated the BRCA1 Arg1699Gln mutation to be patho-
genic. Moreover, two of the splice site programmes pre-
dicted the BRCA2 nucleotide 859 ? 4A[G/c.631 ?
4A[G mutation to have an effect on splicing of exon 7,
while the third one (NetGene2) was unable to ﬁnd both the
wild type and the mutated splice site. It was therefore
decided to analyse the BRCA2 nucleotide 859 ? 4A[
G/c.631 ? 4A[G mutation by functional analysis using
exon trapping. A fragment including BRCA2 exon 7 con-
taining either the wild-type or the nucleotide 859 ?
4A[G/c.631 ? 4A[G mutation, respectively, 148 bp
of intron 6 (IVS6), and 344 bp of intron 7 (IVS7) was
cloned into the minigene vector pSPL3. The wild-type and
mutant constructs was then transfected into COS-7 cells (in
duplicates) and after 48 h mRNA was puriﬁed and exam-
ined by RT–PCR in duplicate on a 2% agarose gel
(Fig. 3a). The normal wild-type BRCA2 exon 7 generated
one transcript comprising the expected 292 bp and a very
faint band of 177 bp, while the BRCA2 exon 7 nucleotide
A>G
a
b
G>A
Exon 7 Intron 7
Fig. 2 Identiﬁcation of the BRCA1 nucleotide 5215G[
A/c.5096G[A mutation, and the BRCA2 nucleotide 859 ? 4A[
G/c.631 ? 4A[G mutation. DNA was puriﬁed from the patient and
the BRCA1 and BRCA2 genes were ampliﬁed using intronic primer
pairs ﬂanking each exon. The PCR products were pre-screened by
dHPLC (denaturing high performance liquid chromatography) and
sequenced. The analysis revealed a a BRCA1 nucleotide 5215G[
A/c.5096G[A mutation and a b BRCA2 nucleotide 859 ? 4A[
G/c.631 ? 4A[G mutation
a
b
Fig. 3 Exon trapping and RT–PCR analysis. a COS-7 cells were
transfected with pSPL3-BRCA2-exon 7 wild-type or pSPL3-BRCA2-
exon 7 mutant plasmids in duplicates. Total RNA was isolated,
RT–PCR analysis was performed and the PCR products were resolved
on a 2% agarose gel. The 292 bp product corresponds to inclusion of
exon 7 (unaltered splicing), while the 172 bp product corresponds to
the exclusion of exon 7. The sizes of the DNA marker (M) are
indicated to the right. b RT–PCR was performed on RNA puriﬁed
from whole blood. The cDNA was ampliﬁed with speciﬁc BRCA2
primers. The sample was separated by agarose gel electrophoresis and
visualized by ethidium bromide staining. Two RT–PCR products
(368 and 253 bp) were obtained from the patient (Lane 2). The PCR
products were cloned and sequence analysis revealed that the 253 bp
band lacked exon 7 (data not shown)
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123859 ? 4A[G/c.631 ? 4A[G mutant yielded one faint
band of 292 bp and a very strong band of 177 bp,
respectively. Sequencing revealed that the 292 bp band
contained exon 7, while the 177 bp band lacked exon 7.
Finally, RT–PCR analysis using mRNA puriﬁed from
whole blood was performed. The PCR products were
analysed on a 1% agarose gel (Fig. 3b). Two PCR products
were ampliﬁed from the patient—a 368 bp band and a
smaller 253 bp band. Cloning and sequence analysis
revealed that the 368 bp band contained exon 7, while the
253 bp band lacked exon 7 (data not shown).
Discussion
Patients double heterozygote for pathogenic mutations in
BRCA1 and BRCA2 are rarely observed, and most reports
involve the three Ashkenazi Jewish founder mutations
BRCA1 nucleotide 185delAG and nucleotide 5382insC and
BRCA2 nucleotide 6174delT (reviewed in [17]) [18–20].
However, four reports describe other BRCA1 and BRCA2
mutations, including a Dutch study describing two patients
with a Dutch BRCA1 founder mutation and two different
BRCA2 frameshift mutations [17], an Australian study
describing one patient with a BRCA1 frameshift mutation
and a BRCA2 splice site mutation [21], while a Korean
study reported two cases of double heterozygosity for
frameshift or nonsense mutations in the BRCA1 and
BRCA2 genes [22]. Finally, a Spanish family with a path-
ogenic BRCA1 Ala1708Glu missense mutation and a
BRCA2 frameshift mutation has been identiﬁed [23].
In this study, we have identiﬁed a Danish breast and
ovarian cancer family with germ-line mutations in the
BRCA1 and BRCA2 genes. Interestingly, the proband, the
probands father, and the probands two children have inher-
ited both mutations. The BRCA1 mutation changes the
aminoacidresidueargenineonposition1699toaglutamine.
Arg1699 is highly conserved from man to plants [24]. It
resides in the BRCT domain of BRCA1, which is involved
in protein–protein interaction (reviewed in [25]). Crystal
structure of the BRCA1 BRCT domain has shown that
Arg1699 participates in the salt bridge with Asp1840 and
Glu1836[26].Moreover,theArg1699Glnmutationchanges
the amino acid residue from basic to polar, and in silico
analysis using the SIFT, Polyphen or PMut software all
regarded the BRCA1 Arg1699Gln mutation as disease-
causing. Finally, we have only observed the mutation in
breast and/or ovarian cancer families, and not in 200 healthy
controls. Still, there have previously been inconclusive
reports regarding the Arg1699Gln. Some in silico based
studieshavenotbeenabletoclassify themutationandgroup
it as a variant of unknown signiﬁcance [27, 28]. In contrast,
other studies consider it to be deleterious using in silico
analysis [29, 30]. Functional studies have shown that the
BRCA1 Arg1699Gln mutation reduces the transcriptional
activity of BRCA1 [31]. Moreover a loss in phosphospeci-
ﬁcity of BRCA1 Gln1699 in its binding to BACH1—com-
paredtoBRCA1Arg1699—hasbeenobserved[32].Finally,
the Arg1699Gln mutation appears to be defective in nuclear
fociformation[33].Moreoveritshouldbenotedthatanother
substitution on this position (Arg1699Trp) is considered
deleterious based on both functional and co-segregation
studies [27]. Together, these data indicate that the BRCA1
Arg1699Gln mutation could be disease-causing, although it
may have a lower penetrance.
TheBRCA2nucleotide859 ? 4A[G/c.631 ? 4A[G
mutation has not previously been reported in the BIC data-
base or in the literature. Several other mutations have been
identiﬁed in this area, including nucleotide 859 ? 2T[
G/c.631 ? 2T[G, which disrupt the splice site consensus
sequence and induce skipping of exon 7 [34], nucleotide
859G[A/c.631G[A,whichalsohasbeenshowntocause
skipping of exon 7 [35], as well as nucleotide 859 ?
1G[A/c.631 ? 1G[A[ 2]. Analysis of the BRCA2
nucleotide859 ? 4A[G/c.631 ? 4A[Gmutationusing
splice site prediction programmes suggested that the muta-
tion affected the exon 7 splice doner site. Therefore we
performedexontrappingexperimentsandRT–PCRanalysis
on RNA puriﬁed from whole blood. The analysis revealed
that the mutation resulted in skipping of exon 7, which
introduces a premature stop codon after incorporation of 18
outofframeaminoacids.Wethereforeclassifythismutation
as disease-causing. Interestingly, even though the family is
double heterozygote for mutations in BRCA1 and BRCA2,
the affected family members do not have breast and/or
ovarian cancer at a younger age than individuals with single
BRCA1 or BRCA2 deleterious mutations. This is in agree-
ment with other studies showing that double heterozygosity
does not seem to lead to a more severe phenotype [17].
In summary, we here report the ﬁrst Danish case of a
patient who is double heterozygote for BRCA1 and BRCA2
mutations. Genetic screening is now offered to all family
members.
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